Compare Core Scientific Inc (CORZ) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Core Scientific Inc vs Neurocrine Biosciences Inc — how do they compare? Core Scientific Inc trades at $15.28 (market cap $4.94B), while Neurocrine Biosciences Inc trades at $141.11 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.9× Core Scientific Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Core Scientific Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Core Scientific Inc for 20 Days and Neurocrine Biosciences Inc for 23 Days on average.
| CORZ | NBIX | |
|---|---|---|
Market Cap | $4.94B | $14.36B |
Volume | 15,630,800 | 1,237,180 |
Sector | Technology | Health |
52-Week High | $29.16 | $185.50 |
52-Week Low | $13.57 | $123.10 |
Typical Hold Time | 20 Days | 23 Days |
Enterprise Value | $7.46B | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CORZ trades at $15.94, down 4.44% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $288.62 million in 2025, with a negative net income margin of -324.9% in 2026. Recent news highlights its pivot to AI data center hosting and executive appointments, while analyst consensus remains strongly bullish with an 86.36% buy rating.
The outlook is mixed: strong analyst support and AI infrastructure growth offer upside potential, but persistent losses, high cash burn, and competitive pressures pose significant risks. Investors face volatility from execution challenges in the capital-intensive data center transition.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Core Scientific Inc
Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.
Read more on CORZ →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
